👁️ Fundus AI shows higher retinal age gap in PD
👁️ Fundus AI shows higher retinal age gap in PD
In a cross-sectional analysis of the AlzEye cohort, a deep-learning fundus model found that 776 people with Parkinson’s disease had a significantly higher retinal age gap than 93,944 without PD, with an adjusted β of 5.92 years (95% CI 5.33-6.51). The model was trained and validated on 19,200 fundus images from 11,052 UK Biobank participants, and the study suggests the retina may capture accelerated aging in PD.
Why It Matters To Your Practice
Retinal age gap is an AI-derived biomarker that compares retina-predicted age with chronological age.
A nearly 6-year higher retinal age gap in PD suggests fundus imaging may reveal neurodegenerative aging signals beyond routine eye findings.
For clinicians using ophthalmic imaging, this points to a possible future role for retinal AI in systemic disease stratification.
Clinical Implications
Do not use retinal age gap to diagnose PD today; this was an observational association study, not a diagnostic accuracy trial.
If validated prospectively, fundus AI could become a low-friction adjunct for identifying patients who may warrant closer neurologic assessment or research enrollment.
This may be especially relevant in older adults, as the reported conclusion emphasized individuals with PD aged 50 years and older.
Insights
The study leveraged real-world data from AlzEye, a large retrospective cohort of 154,830 patients aged 40 years and older.
Adjusted linear mixed-effects modeling strengthens the signal, though residual confounding and cross-sectional design still limit causal inference.
The work extends prior retinal age-gap research previously linked to mortality, cardiovascular disease, and kidney failure into Parkinson’s disease.
The Bottom Line
Fundus AI detected an older-appearing retina in PD, with an adjusted retinal age gap of about 5.9 years.
For practice, the near-term value is awareness: retinal imaging may evolve from eye disease detection toward broader neurologic and aging biomarkers.
For now, this is promising signal-generation, not practice-changing screening.